

# SB-334867 (free base)

Catalog No: tcsc2748



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

792173-99-0

**Formula:**

$C_{17}H_{13}N_5O_2$

**Pathway:**

GPCR/G Protein

**Target:**

Orexin Receptor (OX Receptor)

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 49$  mg/mL (153.45 mM)

**Alternative Names:**

SB334867A free base

**Observed Molecular Weight:**

319.32

## Product Description

SB-334867 free base is a selective non-peptide orexin OX1 receptor antagonist with a pK<sub>b</sub> value of 7.2.


IC<sub>50</sub> value: 7.2 (pK<sub>b</sub>) [1]

Target: orexin OX1 receptor

in vitro: SB-334867-A inhibited the orexin-A (10 nM) and orexin-B (100 nM)-induced calcium responses (pK(B)=7.27±0.04 and 7.23±0.03 respectively, n=8), but had no effect on the UTP (3 µM)-induced calcium response in CHO-OX(1) cells. SB-334867-A (10 µM) also inhibited OX(2) mediated calcium responses (32.7±1.9% versus orexin-A) [1].

in vivo: Single-unit recordings in anesthetized rats demonstrated the central effects of the selective orexin-1 receptor antagonist SB-334867 (2 mg/kg, intravenous), as it reversed the excitatory effects of orexin-A administration (6 µg, intracerebroventricular) on the activity of locus coeruleus (LC) cells [2]. The ICV injection of SB-334867 alone had no effect on the formalin-induced nociceptive behaviors. Pre-treatment with SB-334867 at a dose of 0.5 nmol significantly attenuated the analgesia induced by morphine (at dose 1.5mg/kg of morphine; interphase and phase 2B and at dose 3mg/kg of morphine just phase 2B of formalin test) [3]. Administered alone, SB-334867 (30 mg/kg, but not lower doses) significantly reduced food intake and most active behaviours (eating, grooming, sniffing, locomotion and rearing), while increasing resting. Pretreatment with SB-334867 dose-dependently blocked these effects of orexin-A, with significant antagonism evident at dose levels (3-10 mg/kg) below those required to produce intrinsic behavioural effects under present test conditions in rats [4].

Toxicity: Acute systemic treatment with the selective orexin-1 (OX1R) antagonist SB-334867 reduces food intake in rats, an effect associated with an acceleration in behavioural satiety and unrelated to gross behavioural disruption, alterations in palatability, or toxicity.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!